

## Sequence information

Length: <b>258 AA</b> [This is the length of the unprocessed precursor]	Molecular weight: <b>29335 Da</b> [This is the MW of the unprocessed precursor]	CRC64: <b>0F7EBAE62069A5D0</b> [This is a checksum on the sequence]
---	---	---

10	20	30	40	50	60
MVKIIFVFFI	FLSSFSYAND	DKLYRADSRP	PDEIKQSGGL	MPRGQSEYFD	RGTMNINLY
70	80	90	100	110	120
DHARGTQTGF	VRHDDGYVST	SISLRSALHV	GQTILSGHST	YYIYVIATAP	NMFNVNDVLG
130	140	150	160	170	180
AYSPHPDEQE	VSALGGIPYS	QIYGWYRVHF	GVLDEQLHRN	RGYRDRYYSN	LDIAPAADGY
190	200	210	220	230	240
GLAGFPPEHR	AWREEPWIHH	APPGCGNAPR	SSMSNTCDEK	TQSLGVKFLD	EYQSKVKRQI
250					
FSGYQSDIDT	HNRIKDEL				

P01555 in  
FASTA format

[View entry in original Swiss-Prot format](#)

[View entry in raw text format \(no links\)](#)

[Report form for errors/updates in this Swiss-Prot entry](#)

BLAST

BLAST submission on  
ExPASy/SIB  
or at NCBI (USA)



Sequence analysis tools: ProtParam,  
ProtScale, Compute pI/Mw,  
PeptideMass, PeptideCutter,  
Dotlet (Java)



ScanProsite,  
MotifScan



Search the SWISS-MODEL  
Repository



ExPASy Home page

Site Map

Search ExPASy

Contact us

Swiss-Prot

Hosted by NCSC US

Mirror sites:

Bolivia

Canada


China

Switzerland

Taiwan

The Korean ExPASy site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

*Search Notes keep in file!*

 <a href="#">ExPASy Home page</a>	<a href="#">Site Map</a>	<a href="#">Search ExPASy</a>	<a href="#">Contact us</a>	<a href="#">Swiss-Prot</a>		
<a href="#">Hosted by NCSC US</a>	<a href="#">Mirror sites:</a>	<a href="#">Bolivia</a>	<a href="#">Canada</a>	<a href="#">China</a>	<a href="#">Switzerland</a>	<a href="#">Taiwan</a>

The Korean ExPASy site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

Search  ▼ for

# NiceProt View of Swiss-Prot: P01555

[Printer-friendly view](#)[Quick BlastP search](#)

[\[General\]](#) [\[Name and origin\]](#) [\[References\]](#) [\[Comments\]](#) [\[Cross-references\]](#)  
[\[Keywords\]](#) [\[Features\]](#) [\[Sequence\]](#) [\[Tools\]](#)

*Note: most headings are clickable, even if they don't appear as links. They link to the [user manual](#) or [other documents](#).*

**General information about the entry**

Entry name	CHTA_VIBCH
Primary accession number	P01555
Secondary accession numbers	Q56634 Q9JPV1
Entered in Swiss-Prot in	Release 01, July 1986
Sequence was last modified in	Release 02, October 1986
Annotations were last modified in	Release 41, February 2003
<b>Name and origin of the protein</b>	
Protein name	Cholera enterotoxin, A chain [Precursor]
Synonyms	NAD(+)-diphthamide ADP-ribosyltransferase EC <u>2.4.2.36</u> Cholera enterotoxin A subunit
Gene name	CTXA or TOXA or <u>VC1457</u>
From	<u>Vibrio cholerae</u> [TaxID: <u>666</u> ]
Taxonomy	<u>Bacteria</u> ; <u>Proteobacteria</u> ; <u>Gammaproteobacteria</u> ; <u>Vibrionales</u> ; <u>Vibrionaceae</u> ; <u>Vibrio</u> .
<b>References</b>	
[1]	SEQUENCE FROM NUCLEIC ACID. STRAIN=El Tor 2125; MEDLINE=84068199; PubMed=6646234; [ <u>NCBI</u> , <u>ExPASy</u> , <u>EBI</u> , <u>Israel</u> , <u>Japan</u> ] <u>Mekalanos J.J.</u> , <u>Swartz D.J.</u> , <u>Pearson G.D.N.</u> , <u>Harford N.</u> , <u>Groyne F.</u> , <u>de Wilde M.</u> ; "Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development."; Nature 306:551-557(1983).
[2]	SEQUENCE FROM NUCLEIC ACID. STRAIN=Classical 569B / ATCC 25870 / Serotype O1; MEDLINE=91355224; PubMed=1883840; [ <u>NCBI</u> , <u>ExPASy</u> , <u>EBI</u> , <u>Israel</u> , <u>Japan</u> ] <u>Dams E.</u> , <u>de Wolf M.</u> , <u>Dierick W.</u> ; "Nucleotide sequence analysis of the CT operon of the <i>Vibrio cholerae</i>

	classical strain 569B."; Biochim. Biophys. Acta 1090:139-141(1991).
[3]	SEQUENCE FROM NUCLEIC ACID. <b>STRAIN</b> =1854 / O139-Bengal; <u>Yamamoto K.</u> , <u>Do V.G.R.F.</u> , <u>Xu M.</u> , <u>Iida T.</u> , <u>Miwatani T.</u> , <u>Albert M.J.</u> , <u>Honda T.</u> ; Submitted (MAY-1994) to the EMBL/GenBank/DDBJ databases.
[4]	SEQUENCE FROM NUCLEIC ACID. <b>STRAIN</b> =El Tor 2125; <u>Dams E.</u> , <u>de Wolf M.</u> , <u>Dierick W.</u> ; Submitted (MAY-1991) to the EMBL/GenBank/DDBJ databases.
[5]	SEQUENCE FROM NUCLEIC ACID. <b>STRAIN</b> =KNIH002; <u>Shin H.J.</u> , <u>Park Y.C.</u> , <u>Kim Y.C.</u> ; "Cloning and nucleotide sequence analysis of the virulence gene cassette from <i>Vibrio cholerae</i> KNIH002 isolated in Korea."; <i>Misainmurhag Hoiji</i> 35:205-210(1999).
[6]	SEQUENCE FROM NUCLEIC ACID. <b>STRAIN</b> =El Tor N16961 / Serotype O1; MEDLINE=20406833; PubMed=10952301; [ <u>NCBI</u> , <u>ExPASy</u> , <u>EBI</u> , <u>Israel</u> , <u>Japan</u> ] <u>Heidelberg J.F.</u> , <u>Eisen J.A.</u> , <u>Nelson W.C.</u> , <u>Clayton R.A.</u> , <u>Gwinn M.L.</u> , <u>Dodson R.J.</u> , <u>Haft D.H.</u> , <u>Hickey E.K.</u> , <u>Peterson J.D.</u> , <u>Umayam L.A.</u> , <u>Gill S.R.</u> , <u>Nelson K.E.</u> , <u>Read T.D.</u> , <u>Tettelin H.</u> , <u>Richardson D.</u> , <u>Ermolaeva M.D.</u> , <u>Vamathevan J.</u> , <u>Bass S.</u> , <u>Qin H.</u> , <u>Dragoi I.</u> , <u>Sellers P.</u> , <u>McDonald L.</u> , <u>Utterback T.</u> , <u>Fleischmann R.D.</u> , <u>Nierman W.C.</u> , <u>White O.</u> , <u>Salzberg S.L.</u> , <u>Smith H.O.</u> , <u>Colwell R.R.</u> , <u>Mekalanos J.J.</u> , <u>Venter J.C.</u> , <u>Fraser C.M.</u> ; "DNA sequence of both chromosomes of the cholera pathogen <i>Vibrio cholerae</i> ."; <i>Nature</i> 406:477-483(2000).
[7]	SEQUENCE OF 1-212 FROM NUCLEIC ACID. <b>STRAIN</b> =Classical 569B / ATCC 25870 / Serotype O1; MEDLINE=85006737; PubMed=6090390; [ <u>NCBI</u> , <u>ExPASy</u> , <u>EBI</u> , <u>Israel</u> , <u>Japan</u> ] <u>Lockman H.A.</u> , <u>Galen J.E.</u> , <u>Kaper J.B.</u> ;

	<p>"Vibrio cholerae enterotoxin genes: nucleotide sequence analysis of DNA encoding ADP-ribosyltransferase.";</p> <p><u>J. Bacteriol.</u> 159:1086-1089(1984).</p>
[8]	<p>SEQUENCE OF <u>213-258</u> FROM NUCLEIC ACID.</p> <p>MEDLINE=84061784; PubMed=6315707; [<u>NCBI</u>, <u>ExPASy</u>, <u>EBI</u>, <u>Israel</u>, <u>Japan</u>]</p> <p><u>Lockman H.</u>, <u>Kaper J.B.</u>;</p> <p>"Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin.";</p> <p><u>J. Biol. Chem.</u> 258:13722-13726(1983).</p>
[9]	<p>SEQUENCE OF <u>19-27</u>.</p> <p>MEDLINE=81212799; PubMed=7238869; [<u>NCBI</u>, <u>ExPASy</u>, <u>EBI</u>, <u>Israel</u>, <u>Japan</u>]</p> <p><u>Duffy L.K.</u>, <u>Peterson J.W.</u>, <u>Kurosky A.</u>;</p> <p>"Isolation and characterization of a precursor form of the 'A' subunit of cholera toxin.";</p> <p><u>FEBS Lett.</u> 126:187-190(1981).</p>
[10]	<p>SEQUENCE OF <u>19-38</u> AND <u>213-232</u>.</p> <p>MEDLINE=76259136; PubMed=955672; [<u>NCBI</u>, <u>ExPASy</u>, <u>EBI</u>, <u>Israel</u>, <u>Japan</u>]</p> <p><u>Klapper D.G.</u>, <u>Finkelstein R.A.</u>, <u>Capra J.D.</u>;</p> <p>"Subunit structure and N-terminal amino acid sequence of the three chains of cholera enterotoxin.";</p> <p><u>Immunochemistry</u> 13:605-611(1976).</p>
[11]	<p>SEQUENCE OF <u>27-72</u> AND <u>111-139</u>.</p> <p>MEDLINE=79169830; PubMed=437113; [<u>NCBI</u>, <u>ExPASy</u>, <u>EBI</u>, <u>Israel</u>, <u>Japan</u>]</p> <p><u>Lai C.-Y.</u>, <u>Cancedda F.</u>, <u>Chang D.</u>;</p> <p>"Primary structure of cholera toxin subunit A1: isolation, partial sequences and alignment of the BrCN fragments.";</p> <p><u>FEBS Lett.</u> 100:85-89(1979).</p>
[12]	<p>SEQUENCE OF <u>213-258</u>.</p> <p>MEDLINE=82053094; PubMed=7028752; [<u>NCBI</u>, <u>ExPASy</u>, <u>EBI</u>, <u>Israel</u>, <u>Japan</u>]</p> <p><u>Duffy L.K.</u>, <u>Peterson J.W.</u>, <u>Kurosky A.</u>;</p>

"Covalent structure of the gamma chain of the A subunit of cholera toxin.";

J. Biol. Chem. 256:12252-12256(1981).

[13] X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).

MEDLINE=95387395; PubMed=7658473; [NCBI, ExPASy, EBI, Israel, Japan]

Zhang R.G., Scott D.L., Westbrook M.L., Nance S., Spangler B.D., Shipley G.G., Westbrook E.M.;

"The three-dimensional crystal structure of cholera toxin.";

J. Mol. Biol. 251:563-573(1995).

### Comments

**FUNCTION:** THE ALPHA/GAMMA CHAIN (A SUBUNIT) IS AN ADP-RIBOSYLATING TOXIN.

**CATALYTIC ACTIVITY:**  $\text{NAD}^+$  + peptide diphthamide = nicotinamide + peptide N-(ADP-D-ribosyl)diphthamide.

**SUBUNIT:** CONTAINS 3 KINDS OF CHAINS. AN ALPHA AND A GAMMA CHAIN (FROM THE SAME PRECURSOR MOLECULE), LINKED BY AN INTERCHAIN DISULFIDE BOND, ASSOCIATE NONCOVALENTLY WITH AN AGGREGATE OF 4 TO 6 BETA CHAINS.

### Copyright

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch))

### Cross-references


EMBL	X00171; CAA24995.1; -. [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	X58785; CAA41590.1; -. [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	D30053; BAA06290.1; [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	X58786; CAA41592.1; -. [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	K02679; AAA27514.1; -. [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	AF175708; [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] AAD51359.1; -. [ <a href="#">CoDingSequence</a> ]
	AE004224; [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] AAF94614.1; -. [ <a href="#">CoDingSequence</a> ]
	K01170; AAA27572.1; -. [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
	D30052; BAA06288.1; [ <a href="#">EMBL</a> / <a href="#">GenBank</a> / <a href="#">DDBJ</a> ] [ <a href="#">CoDingSequence</a> ]
PIR	A05129; XVVCA.
PDB	1XPB; 01-APR-97. [ <a href="#">ExPASy</a> / <a href="#">RCSB</a> ]
	1XTC; 01-AUG-96. [ <a href="#">ExPASy</a> / <a href="#">RCSB</a> ] <a href="#">Detailed list of linked structures.</a>
TIGR	VC1457; -.
InterPro	<a href="#">IPR001144</a> ; Enterotoxin_A. <a href="#">Graphical view of domain structure.</a>
Pfam	<a href="#">PF01375</a> ; Enterotoxin_A; 1.
PRINTS	<a href="#">PR00771</a> ; ENTEROTOXINA.
ProDom	[ <a href="#">Domain structure</a> / <a href="#">List of seq. sharing at least 1 domain</a> ]
HOBACGEN	[ <a href="#">Family</a> / <a href="#">Alignment</a> / <a href="#">Tree</a> ]
BLOCKS	<a href="#">P01555</a> .
ProtoNet	<a href="#">P01555</a> .
ProtoMap	<a href="#">P01555</a> .
PRESAGE	<a href="#">P01555</a> .

DIP	P01555.
ModBase	P01555.
SWISS-2DPAGE	Get region on 2D PAGE.


## Keywords

Enterotoxin; Signal; NAD; Transferase; Glycosyltransferase; 3D-structure; Complete proteome.

## Features



Feature table viewer



Feature aligner

Key	From	To	Length	Description
SIGNAL	<u>1</u>	<u>18</u>	18	
CHAIN	<u>19</u>	<u>212</u>	194	CHOLERA ENTEROTOXIN, CHAIN-A1 (ALPHA).
CHAIN	<u>213</u>	<u>258</u>	46	CHOLERA ENTEROTOXIN, CHAIN-A2 (GAMMA).
DISULFID	<u>217</u>	<u>217</u>		INTERCHAIN (WITH GAMMA CHAIN).
ACT_SITE	<u>62</u>	<u>62</u>		INTERACT WITH NAD (BY SIMILARITY).
ACT_SITE	<u>130</u>	<u>130</u>		BY SIMILARITY.
CONFLICT	<u>20</u>	<u>20</u>		D -> N (IN REF. <u>9</u> ).
CONFLICT	<u>37</u>	<u>37</u>		S -> R (IN REF. <u>10</u> ).
CONFLICT	<u>39</u>	<u>39</u>		G -> L (IN REF. <u>11</u> ).
CONFLICT	<u>45</u>	<u>46</u>		QS -> SE (IN REF. <u>11</u> ).
CONFLICT	<u>111</u>	<u>111</u>		N -> L (IN REF. <u>11</u> ).
CONFLICT	<u>132</u>	<u>132</u>		S -> A (IN REF. <u>11</u> ).
CONFLICT	<u>213</u>	<u>213</u>		M -> I (IN REF. <u>1</u> ).
CONFLICT	<u>247</u>	<u>248</u>		DI -> ID (IN REF. <u>12</u> ).
CONFLICT	<u>256</u>	<u>256</u>		D -> N (IN REF. <u>12</u> ).
STRAND	<u>24</u>	<u>27</u>	4	
HELIX	<u>31</u>	<u>37</u>	7	
TURN	<u>38</u>	<u>38</u>	1	
STRAND	<u>39</u>	<u>40</u>	2	
TURN	<u>43</u>	<u>44</u>	2	
TURN	<u>48</u>	<u>49</u>	2	

9 differences



HELIX	<u>59</u>	<u>63</u>	5
TURN	<u>64</u>	<u>64</u>	1
TURN	<u>75</u>	<u>76</u>	2
STRAND	<u>77</u>	<u>81</u>	5
HELIX	<u>85</u>	<u>89</u>	5
TURN	<u>90</u>	<u>91</u>	2
TURN	<u>96</u>	<u>97</u>	2
STRAND	<u>101</u>	<u>106</u>	6
TURN	<u>110</u>	<u>111</u>	2
STRAND	<u>112</u>	<u>114</u>	3
HELIX	<u>115</u>	<u>119</u>	5
HELIX	<u>120</u>	<u>122</u>	3
HELIX	<u>126</u>	<u>128</u>	3
STRAND	<u>130</u>	<u>134</u>	5
STRAND	<u>137</u>	<u>138</u>	2
TURN	<u>139</u>	<u>141</u>	3
STRAND	<u>142</u>	<u>148</u>	7
STRAND	<u>153</u>	<u>159</u>	7
TURN	<u>161</u>	<u>162</u>	2
HELIX	<u>165</u>	<u>168</u>	4
TURN	<u>169</u>	<u>170</u>	2
HELIX	<u>176</u>	<u>178</u>	3
TURN	<u>187</u>	<u>188</u>	2
HELIX	<u>190</u>	<u>193</u>	4
TURN	<u>195</u>	<u>196</u>	2
HELIX	<u>197</u>	<u>199</u>	3
TURN	<u>200</u>	<u>200</u>	1
TURN	<u>203</u>	<u>204</u>	2
HELIX	<u>215</u>	<u>251</u>	37
TURN	<u>252</u>	<u>253</u>	2
HELIX	<u>254</u>	<u>258</u>	5

10	20	30	40	50	60
MVKIIFVFFI	FLSSFSYAND	DKLYRADSRP	PDEIKQSGGL	MPRGQSEYFD	RGTQMNINLY
70	80	90	100	110	120
DHARGTQTGF	VRHDDGYVST	SISLRSAPLV	GQTILSGHST	YIYVIATAP	NMFNVNDVLG
130	140	150	160	170	180
AYSPHPDEQE	VSALGGIPYS	QIYGWYRVHF	GVLDEQLHRN	RGYRDRYYSN	LDIAPAADGY
190	200	210	220	230	240
GLAGFPPEHR	AWREEPWIHH	APPGCGNAPR	SSMSNTCDEK	TQSLGVKFLD	EYQSKVKRQI
250					
FSGYQSDIDT	HNRIEDEL				

Q8L356 in  
FASTA format

[View entry in original TrEMBL format](#)

[View entry in raw text format \(no links\)](#)

[Request for annotation of this TrEMBL entry](#)

BLAST

BLAST submission on  
ExpASY/SIB  
or at NCBI (USA)



Sequence analysis tools: ProtParam,  
ProtScale, Compute pI/Mw,  
PeptideMass, PeptideCutter,  
Dotlet (Java)



ScanProsite,  
MotifScan



Search the SWISS-MODEL  
Repository



ExpASY Home page

Site Map

Search ExpASY

Contact us

Swiss-Prot

Hosted by NCSC US

Mirror sites:

Bolivia

Canada

China

Switzerland

Taiwan

The Korean ExpASY site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

 <a href="#">ExPASy Home page</a>	<a href="#">Site Map</a>	<a href="#">Search ExPASy</a>	<a href="#">Contact us</a>	<a href="#">Swiss-Prot</a>		
<a href="#">Hosted by NCSC US</a>	<a href="#">Mirror sites:</a>	<a href="#">Bolivia</a>	<a href="#">Canada</a>	<a href="#">China</a>	<a href="#">Switzerland</a>	<a href="#">Taiwan</a>

The Korean ExPASy site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

Search  for

# NiceProt View of TrEMBL: Q8L356

[Printer-friendly view](#)[Quick BlastP search](#)

[\[General\]](#) [\[Name and origin\]](#) [\[References\]](#) [\[Comments\]](#) [\[Cross-references\]](#)  
[\[Keywords\]](#) [\[Features\]](#) [\[Sequence\]](#) [\[Tools\]](#)

*Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.*

**General information about the entry**

Entry name	Q8L356
Primary accession number	Q8L356
Secondary accession numbers	None
Entered in TrEMBL in	Release 22, October 2002
Sequence was last modified in	Release 22, October 2002
Annotations were last modified in	Release 24, June 2003

### Name and origin of the protein

Protein name	Cholera toxin A subunit
Synonyms	None
Gene name	CTXA
From	<u>Vibrio cholerae O27</u> [TaxID: <u>185331</u> ]
Taxonomy	<u>Bacteria</u> ; <u>Proteobacteria</u> ; <u>Gammaproteobacteria</u> ; <u>Vibrionales</u> ; <u>Vibrionaceae</u> ; <u>Vibrio</u> .

### References

- [1] SEQUENCE FROM NUCLEIC ACID.  
STRAIN=365-96;  
MEDLINE=21950561; PubMed=11953381; [NCBI, ExPASy, EBI, Israel,  
Japan]  
Li M., Shimada T., Morris J.G. Jr., Sulakvelidze A., Sozhamannan S.;  
"Evidence for the emergence of non-O1 and non-O139 *Vibrio cholerae*  
strains with pathogenic potential by exchange of O-antigen biosynthesis  
regions.";  
Infect. Immun. 70:2441-2453(2002).

### Comments

None

### Cross-references

EMBL	AF390572; <a href="#">[EMBL / GenBank / DDBJ]</a> AAM22586.1; -. <a href="#">[CoDingSequence]</a>
GO	<a href="#">GO:0005576</a> ; Cellular component: extracellular ( <i>inferred from electronic annotation</i> ). <a href="#">GO:0015070</a> ; Molecular function: toxin activity ( <i>inferred from electronic annotation</i> ). <a href="#">GO:0009405</a> ; Biological process: pathogenesis ( <i>inferred from electronic annotation</i> ).
InterPro	<a href="#">IPR001144</a> ; Enterotoxin_A. <a href="#">Graphical view of domain structure.</a>
Pfam	<a href="#">PF01375</a> ; Enterotoxin_A; 1.
PRINTS	<a href="#">PR00771</a> ; ENTEROTOXINA.
ProDom	<a href="#">[Domain structure / List of seq. sharing at least 1 domain]</a>
HOBACGEN	<a href="#">[Family / Alignment / Tree]</a>
ProtoMap	<a href="#">Q8L356</a> .
PRESAGE	<a href="#">Q8L356</a> .
ModBase	<a href="#">Q8L356</a> .
SWISS-2DPAGE	<a href="#">Get region on 2D PAGE.</a>

**Keywords**

None

**Features**

None

**Sequence information**

Length: 258 AA	Molecular weight: 29336 Da	CRC64: 0F7EBAEE0069A5D0 [This is a checksum on the sequence]
-------------------	-------------------------------	---

<b>Length: 258 AA</b>		<b>Molecular weight: 29362 Da</b>	<b>CRC64: 3EA358C7F8BA8BF7 [This is a checksum on the sequence]</b>		
10	20	30	40	50	60
MVKIIFVFFI	FLSSFSYAND	DKLYRADSRP	PDEIKQSGGL	MPRGQNEYFD	RGTQMNINLY
70	80	90	100	110	120
DHARGTQTGF	VRHDDGYVST	SISLRSALHV	GQTILSGHST	YYIYVIATAP	NMFNVNDVLG
130	140	150	160	170	180
AYSPHPDEQE	VSALGGIPYS	QIYGWYRVHF	GVLDEQLHRN	RGYRDRYYSN	LDIAPAADGY
190	200	210	220	230	240
GLAGFPPEHR	AWREEPWIHH	APPGCGNAPR	SSMSNTCDEK	TQSLGVKFLD	EYQSKVKRQI
250					
FSGYQSDIDT	HNRIKDEL				
					<b>Q8VLI6 in FASTA format</b>

[View entry in original TrEMBL format](#)

[View entry in raw text format \(no links\)](#)

[Request for annotation of this TrEMBL entry](#)

**BLAST**

[BLAST submission on ExPASy/SIB](#)  
or at [NCBI \(USA\)](#)



Sequence analysis tools: [ProtParam](#),  
[ProtScale](#), [Compute pI/Mw](#),  
[PeptideMass](#), [PeptideCutter](#),  
[Dotlet \(Java\)](#)



[ScanProsite](#),  
[MotifScan](#)



Search the [SWISS-MODEL Repository](#)



[ExpASY Home page](#)

[Site Map](#)

[Search ExpASY](#)

[Contact us](#)

[Swiss-Prot](#)

[Hosted by NCSC US](#)

[Mirror sites:](#)

[Bolivia](#)


[Canada](#)

[China](#)

[Switzerland](#)

[Taiwan](#)

The Korean ExpASY site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

 <a href="#">ExPASy Home page</a>	<a href="#">Site Map</a>	<a href="#">Search ExPASy</a>	<a href="#">Contact us</a>	<a href="#">Swiss-Prot</a>		
<a href="#">Hosted by NCSC US</a>	<a href="#">Mirror sites:</a>	<a href="#">Bolivia</a>	<a href="#">Canada</a>	<a href="#">China</a>	<a href="#">Switzerland</a>	<a href="#">Taiwan</a>

The Korean ExPASy site, [kr.expasy.org](http://kr.expasy.org), is temporarily not available.

Search  for

# NiceProt View of TrEMBL: Q8VLI6

[Printer-friendly view](#)[Quick BlastP search](#)

[\[General\]](#) [\[Name and origin\]](#) [\[References\]](#) [\[Comments\]](#) [\[Cross-references\]](#)  
[\[Keywords\]](#) [\[Features\]](#) [\[Sequence\]](#) [\[Tools\]](#)

*Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.*

**General information about the entry**

Entry name	Q8VLI6
Primary accession number	Q8VLI6
Secondary accession numbers	None
Entered in TrEMBL in	Release 20, March 2002
Sequence was last modified in	Release 20, March 2002
Annotations were last modified in	Release 24, June 2003

### Name and origin of the protein

Protein name	CtxA
Synonyms	None
Gene name	CTXA
From	<u>Vibrio cholerae</u> [TaxID: 666]
Taxonomy	<u>Bacteria</u> ; <u>Proteobacteria</u> ; <u>Gammaproteobacteria</u> ; <u>Vibrionales</u> ; <u>Vibrionaceae</u> ; <u>Vibrio</u> .

### References

- [1] SEQUENCE FROM NUCLEIC ACID.  
**STRAIN=203-93, and 571-88;**  
Li M., Chen Y., Kotetishvili M., Stine O.C., Morris J.G. Jr., Sulakvelidze A., Sozhamannan S.;  
 "Genetic Analysis of the Virulence Regions, CTX f prophage and Vibrio Pathogenicity Island (VPI), in Diverse, Non-epidemic Serogroup Strains of Vibrio cholerae.";  
 Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
- [2] SEQUENCE FROM NUCLEIC ACID.  
**STRAIN=1322-69;**  
Li M., Chen Y., Kotetishvili M., Stine O.C., Morris J.G. Jr., Sulakvelidze A., Sozhamannan S.;  
 "Genetic Analysis of the Virulence Regions, CTX f prophage and Vibrio Pathogenicity Island (VPI), in Diverse, Non-epidemic Serogroup Strains of Vibrio cholerae.";  
 Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.

### Comments



None

**Cross-references**

EMBL	AF463401; [EMBL / GenBank / DDBJ] AAL69945.1; -. [CoDingSequence] AF452584; [EMBL / GenBank / DDBJ] AAL60525.1; -. [CoDingSequence] AF463400; [EMBL / GenBank / DDBJ] AAL69944.1; -. [CoDingSequence]
GO	<u>GO:0005576</u> ; Cellular component: extracellular ( <i>inferred from electronic annotation</i> ). <u>GO:0015070</u> ; Molecular function: toxin activity ( <i>inferred from electronic annotation</i> ). <u>GO:0009405</u> ; Biological process: pathogenesis ( <i>inferred from electronic annotation</i> ).
InterPro	<u>IPR001144</u> ; Enterotoxin_A. <u>IPR000886</u> ; ER_target. <u>Graphical view of domain structure.</u>
Pfam	<u>PF01375</u> ; Enterotoxin_A; 1.
PRINTS	<u>PR00771</u> ; ENTEROTOXINA.
PROSITE	<u>PS00014</u> ; ER_TARGET; 1.
ProDom	[ <u>Domain structure</u> / <u>List of seq. sharing at least 1 domain</u> ]
HOBACGEN	[ <u>Family</u> / <u>Alignment</u> / <u>Tree</u> ]
ProtoMap	<u>Q8VLI6</u> .
PRESAGE	<u>Q8VLI6</u> .
ModBase	<u>Q8VLI6</u> .
SWISS-2DPAGE	<u>Get region on 2D PAGE.</u>

**Keywords**

None

**Features**

None

**Sequence information**

# WEST Search History



DATE: Thursday, June 26, 2003

## Set Name Query

side by side

## Hit Count Set Name

result set

*DB=USPT; PLUR=YES; OP=AND*

L1	hsv.clm.	394	L1
L2	L1 and meningitidis.clm.	0	L2
L3	L1 and meningitidis.clm.	1	L3
L4	L1 and (gd-2 or gd2).clm.	3	L4
L5	L1 and (rota\$ and syncytial).clm.	9	L5
L6	helicobacter.clm. and pylori.clm. urease.clm. and vaccin\$.clm.	6	L6
L7	p4.clm.	1	L7
L8	haemophilus.clm. and p4.clm. and p6.clm.	0	L8
L9	haemophilus.clm. and p4.clm.	0	L9
L10	p4.clm. and p6.clm. and hap\$.clm.	0	L10
L11	p4.clm. and p6.clm.	83	L11
L12	L11 and influenz\$.clm.	0	L12
L13	influenz\$.clm.	1067	L13
L14	L13 and (opp\$ and adher\$).clm.	1	L14
L15	L13 and (omp\$ and adher\$).clm.	0	L15
L16	L13 and (omp\$ ).clm.	5	L16
L17	L13 and (omp near10 p4)	4	L17
L18	L13 and (hap or haps! or hap-s!)	11	L18
L19	('6245337')[PN]	1	L19

END OF SEARCH HISTORY

**WEST****Search Results - Record(s) 1 through 1 of 1 returned.**

L19: Entry 1 of 1

File: USPT

Jun 12, 2001

US-PAT-NO: 6245337

DOCUMENT-IDENTIFIER: US 6245337 B1

TITLE: Haemophilus adherence and penetration proteins

DATE-ISSUED: June 12, 2001

US-CL-CURRENT: 424/256.1, 424/190.1, 435/69.1, 435/69.3, 530/350INT-CL: [07] A61 K 39/102[Previous Page](#)[Next Page](#)

# WEST Search History

DATE: Thursday, June 26, 2003

Set Name Query

side by side

Hit Count Set Name

result set

*DB=USPT; PLUR=YES; OP=AND*

L1	((((cholera or ctx or rctx or cta or adpribosy\$ or ribosylat\$ or adp-ribosyla\$ or mucosal).ti. )and (vibrio or cholera) )and (site or position or location or sitedirect\$ or positions or sites or locations) ) and 29) (e29 or e-29 or glu29 or glu-29) same	34	L1
L2	(cholera or ctx or rctx or cta or adpribosy\$ or ribosylat\$ or adp-ribosyla\$ or mucosal) (e29 or e-29 or glu29 or glu-29).clm. and	0	L2
L3	(cholera or ctx or rctx or cta or adpribosy\$ or ribosylat\$ or adp-ribosyla\$ or mucosal).clm.	0	L3
L4	(e29 or e-29 or glu29 or glu-29).clm.	6	L4
L5	(e29 or e-29 or glu29 or glu-29) and cholera	2	L5
L6	(e29 or e-29 or glu29 or glu-29) and (adpribosy\$ or adp)	10	L6

END OF SEARCH HISTORY

08955989 20245740 PMID: 10781860

**Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT- E29H**

Tebbey P W; Scheuer C A; Peek J A; Zhu D; LaPierre N A; Green B A; Phillips E D; Ibraghimov A R; Eldridge J H; Hancock G E

Department of Immunology Research, Wyeth-Lederle Vaccines, 211 Bailey Road, West Henrietta, NY 14586-9728, USA.

Vaccine (ENGLAND) Jun 1 2000, 18 (24) p2723-34, ISSN 0264-410X

Journal Code: 8406899

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

We exploited the powerful adjuvant properties of cholera holotoxin (CT) to create a mucosally administered subunit vaccine against respiratory syncytial virus (RSV). A genetically detoxified mutant CT with an E to H substitution at amino acid 29 of the CT-A1 subunit (CT- E29H ) was compared to wild type CT for toxicity and potential use as an intranasal (IN) adjuvant for the natural fusion (F) protein of RSV. When compared to CT the results demonstrated that: (1) CT- E29H binding to GM1 ganglioside was equivalent, (2) ADP-ribosylation of agmatine was 11.7%, and (3) toxicity was attenuated in both Y-1 adrenal (1.2%) and patent mouse gut weight assays. IN vaccination with F protein formulated with CT- E29H induced serum anti-CT and anti-F protein antibodies that were comparable to those obtained after vaccination with equivalent doses of CT. Vaccinations containing CT- E29H at doses of 0.1 microg were statistically equivalent to 1.0 microg in enhancing responses to F protein. Antigen-specific mucosal IgA and anti-RSV neutralizing antibodies were detected in nasal washes and sera, respectively, of mice that had received F protein and 0.1 or 1.0 microg of CT- E29H . Anti-F protein IgA was not detected in the nasal washes from mice IN vaccinated with 0.01 microg CT- E29H or IM with F protein adsorbed to ALOH adjuvant. In addition, the formulation of purified F protein and CT- E29H (0.1 and 1.0 microg) facilitated protection of both mouse lung and nose from live RSV challenge. Collectively, the data have important implications for vaccine strategies that use genetically detoxified mutant cholera holotoxins for the mucosal delivery of highly purified RSV antigens.

Tags: Animal; Female

Descriptors: \*Antigens, Viral--immunology--IM; \*Cholera Toxin--immunology--IM; \*Respiratory Syncytial Viruses--immunology--IM; \*Viral Proteins--immunology--IM; \*Viral Vaccines--immunology--IM; Bronchoalveolar Lavage; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Immunity, Mucosal; Lung--virology--VI; Mice; Mice, Inbred BALB C; Nasal Mucosa--virology--VI

CAS Registry No.: 0 (Antigens, Viral); 0 (Viral Proteins); 0 (Viral Vaccines); 0 (attachment protein G); 0 (respiratory syncytial virus proteins); 9012-63-9 (Cholera Toxin)

Record Date Created: 20000711

Record Date Completed: 20000711

09403284 21169659 PMID: 11270595

**Protective efficacy of rotavirus 2/6-virus-like particles combined with CT- E29H , a detoxified cholera toxin adjuvant.**

Siadat-Pajouh M; Cai L

Department of Viral Vaccine Research, Wyeth-Lederle Vaccines, Pearl River, New York, USA.

Viral immunology (United States) 2001, 14 (1) p31-47, ISSN 0882-8245 Journal Code: 8801552

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Identifying a safe and efficacious mucosal adjuvant is crucial for the development of subunit vaccines against rotavirus and other mucosal pathogens. Moreover, recognition of determinants of protective immunity to rotavirus infection is essential to the design of the means to prevent or control this viral gastrointestinal disease. We have studied the kinetics of systemic and mucosal antibody responses elicited upon mucosal immunization of mice with rotavirus recombinant virus-like particles (rVLPs) alone or combined with a detoxified version of cholera toxin, CT- **E29H** . CT- **E29H** has been shown to maintain the adjuvant effect of parental cholera holotoxin. Both inbred BALB/c and outbred CD-1 mice were immunized with rotavirus VP2/6-rVLPs (2/6-VLPs) combined with CT- **E29H** , orally or intranasally (i.n.), and the comparative efficacy of different formulations was then determined. Rotavirus-specific serum and fecal IgA, IgM, and IgG antibodies were determined by enzyme-linked immunoadsorbent assay (ELISA) weekly (or every other week) following vaccination. Animals then were challenged with a murine rotavirus strain, EDIM. The degree to which vaccinated animals were protected from the wild-type rotavirus challenge was reflected in the levels of viral antigen shed in stools (percent reduction in antigen shedding, PRAS). BALB/c mice immunized by either route produced rotavirus-specific serum IgA, IgM and IgG, as well as fecal IgA and IgG, but not IgM; however, the intranasal immunization induced stronger systemic IgG and IgM responses than did oral immunization. Similar levels of prechallenge rotavirus-specific fecal and serum IgA were detected in both the orally and the i.n. immunized groups. Two immunizations with 2-6VLPs and CT- **E29H** were sufficient to protect BALB/c mice, regardless of the route of administration. PRAS was 99.6, 98.8, and 98.8% for oral, i.n. and the oral + i.n. groups, respectively; in contrast vaccination with 2/6-VLPs alone was not protective (PRAS = 39%), indicating the critical role of CT- **E29H** in inducing protective levels of immune responses. Two of four outbred CD-1 mice that were immunized orally with 2/6-VLPs-CT- **E29H** showed no humoral responses (PRAS, 65%), but four of four i.n. immunized CD-1 mice displayed humoral responses (PRAS, 97.9%). Serum anti-VP6 and VP2 antibodies were detected in all immunoresponsive mice. The combined results in two strains of mice indicate that CTE29H is an effective mucosal adjuvant capable of inducing protective immune responses and suggest that intranasal administration is the preferred route of immunization.

Tags: Animal; Human

Descriptors: \*Capsid--immunology--IM; \*Cholera Toxin--immunology--IM; \*Rotavirus Infections--prevention and control--PC; \*Rotavirus Vaccines--immunology--IM; Adjuvants, Immunologic; Antibodies, Viral--blood--BL; Capsid--genetics--GE; Capsid Proteins; Disease Models, Animal; Feces--chemistry--CH; Immunization; Immunoglobulin A, Secretory--analysis--AN; Mice; Mice, Inbred BALB C; Recombinant Proteins--immunology--IM; Rotavirus--immunology--IM; Rotavirus Infections--immunology--IM; Rotavirus Vaccines--administration and dosage--AD; Virion--genetics--GE; Virion--immunology--IM

09472592 21246685 PMID: 11349048

**Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge.**

Zhang Y; Masi A W; Barniak V; Mountzouros K; Hostetter M K; Green B A  
Department of Immunology, Wyeth Lederle Vaccines, West Henrietta, New York 14586-9728, USA. zhangy4@war.wyeth.com

Infection and immunity (United States) Jun 2001, 69 (6) p3827-36,  
ISSN 0019-9567 Journal Code: 0246127

Contract/Grant No.: AI 24162; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine. However, serotypes not covered by the current conjugate vaccine may still cause pneumococcal disease. To address these serotypes and the remaining otitis media due to Streptococcus pneumoniae, we have been evaluating antigenically conserved proteins from S. pneumoniae as vaccine candidates. A previous report identified a 20-kDa protein with putative human complement C3-proteolytic activity. By utilizing the publicly released pneumococcal genomic sequences, we found the gene encoding the 20-kDa protein to be part of a putative open reading frame of approximately 2,400 bp. We recombinantly expressed a 79-kDa fragment (rPhpA-79) that contains a repeated HxxHxxH motif and evaluated it for vaccine potential. The antibodies elicited by the purified rPhpA-79 protein were cross-reactive to proteins from multiple strains of S. pneumoniae and were against surface-exposed epitopes. Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT- E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain. In contrast, immunization with the 20-kDa portion of the PhpA protein did not protect mice. These results suggest that rPhpA-79 is a potential candidate for use as a vaccine against pneumococcal systemic disease and otitis media.

Tags: Animal; Human; Male; Support, U.S. Gov't, P.H.S.

Descriptors: \*Bacterial Proteins--genetics--GE; \*Endopeptidases  
--immunology--IM; \*Otitis Media--prevention and control--PC; \*Pneumococcal  
Infections--prevention and control--PC; \*Streptococcal Vaccines--immunology  
--IM; \*Streptococcus pneumoniae--immunology--IM; Administration, Intranasal  
; Antibodies, Bacterial--blood--BL; Bacterial Proteins--immunology--IM;  
Endopeptidases--chemistry--CH; Endopeptidases--genetics--GE; Endopeptidas  
es--metabolism--ME; Histidine--chemistry--CH; Immunization; Mice; Mice,  
Inbred CBA; Molecular Sequence Data; Nasopharynx--microbiology--MI; Otitis  
Media--microbiology--MI; Pneumococcal Infections--microbiology--MI;  
Recombinant Proteins--genetics--GE; Recombinant Proteins--immunology--IM;  
Recombinant Proteins--metabolism--ME; Sequence Analysis, DNA

Molecular Sequence Databank No.: GENBANK/AF340221; GENBANK/AF340222;  
GENBANK/AF340223

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Proteins);  
0 (PhpA protein); 0 (Recombinant Proteins); 0 (Streptococcal Vaccines)  
; 71-00-1 (Histidine)

Enzyme No.: EC 3.4.- (Endopeptidases)

Record Date Created: 20010511

Record Date Completed: 20010628

13971796 22242173 PMID: 12355362

**Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice.**

Cutter David; Mason Kathryn W; Howell Alan P; Fink Doran L; Green Bruce A ; St Geme Joseph W; et al

Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.

Journal of infectious diseases (United States) Oct 15 2002, 186 (8) p1115-21, ISSN 0022-1899 Journal Code: 0413675

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: AIM; INDEX MEDICUS

Nontypeable Haemophilus influenzae is a common cause of respiratory tract disease and initiates infection by colonizing the nasopharynx. The H. influenzae Hap adhesin is an autotransporter protein that was discovered because it promotes intimate interaction with human epithelial cells. Hap contains an extracellular domain called Hap(s) that has adhesive and protease activity and an outer membrane domain called Hap(beta) that serves to present Hap(s) on the surface of the cell. Hap(s) purified from nontypeable H. influenzae strain P860295 was used to immunize BALB/c mice intranasally. Immunization stimulated significant mucosal and serum anti-Hap(s) antibody titers, which were augmented by the addition of mutant cholera toxin (CT- E29H) as an adjuvant. Immunization was associated with a marked reduction in the density of nasopharyngeal colonization when mice were challenged with a heterologous strain of nontypeable H. influenzae. These results suggest that intranasal immunization with Hap formulated with CT- E29H may be a valuable vaccine strategy for the prevention of nontypeable H. influenzae disease.

Tags: Animal; Support, Non-U.S. Gov't

Descriptors: \*Bacterial Outer Membrane Proteins--immunology--IM; \*Haemophilus Infections--immunology--IM; \*Haemophilus Infections--prevention and control--PC; \*Haemophilus influenzae--immunology--IM; \*Nasopharynx--immunology--IM; \*Nasopharynx--microbiology--MI; Adjuvants, Immunologic--administration and dosage--AD; Administration, Intranasal; Antibodies, Bacterial--immunology--IM; Bacterial Adhesion--immunology--IM; Bacterial Outer Membrane Proteins--administration and dosage--AD; Bacterial Outer Membrane Proteins--genetics--GE; Blotting, Western; Cell Line; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Epithelial Cells--immunology--IM; Immunity, Mucosal--immunology--IM; Immunization; Immunoglobulin A--immunology--IM; Immunoglobulin G--immunology--IM; Mice; Mice, Inbred BALB C

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Hap protein); 0 (Immunoglobulin A); 0 (Immunoglobulin G)

Record Date Created: 20020930



SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2003/Jun W4

(c) format only 2003 The Dialog Corp.

\*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.

File 5:Biosis Previews(R) 1969-2003/Jun W3

(c) 2003 BIOSIS

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Jun W4

(c) 2003 Inst for Sci Info

File 35:Dissertation Abs Online 1861-2003/May

(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/May

(c) 2003 Sport Information Resource Centre

File 65:Inside Conferences 1993-2003/Jun W4

(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Jun W4

(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/Jun W4

(c) 2003 Elsevier Science B.V.

\*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 91:MANTIS(TM) 1880-2002/Oct

2002 (c) Action Potential

File 94:JICST-EPlus 1985-2003/Jun W4

(c) 2003 Japan Science and Tech Corp(JST)

File 98:General Sci Abs/Full-Text 1984-2003/May

(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/Jun W3

(c) 2003 NewsRx

\*File 135: New newsletters are now added. See Help News135 for the complete list of newsletters.

File 144:Pascal 1973-2003/Jun W2

(c) 2003 INIST/CNRS

File 149:TGG Health&Wellness DB(SM) 1976-2003/Jun W3

(c) 2003 The Gale Group

File 156:ToxFile 1965-2003/Jun W4

(c) format only 2003 The Dialog Corporation

\*File 156: ToxFile has been reloaded. Accession numbers have changed. Please see HELP NEWS 156 for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog Corporation

\*File 159: Cancerlit ceases updating with immediate effect. Please see HELP NEWS.

File 162:Global Health 1983-2003/May

(c) 2003 CAB International

\*File 162: Effective May 1, name changes from CAB Health to Global Health.

File 164:Allied & Complementary Medicine 1984-2003/Jun

(c) 2003 BLHCIS

File 172:EMBASE Alert 2003/Jun W4

(c) 2003 Elsevier Science B.V.

File 266:FEDRIP 2003/May

Comp & dist by NTIS, Intl Copyright All Rights Res

File 369:New Scientist 1994-2003/Jun W3

(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

\*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2003/UD=13826

(c) 2003 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 442:AMA Journals 1982-2003/Dec B2

(c) 2003 Amer Med Assn -FARS/DARS apply

\*File 442: File 442 will be removed from Dialog on June 30, 2003

File 444:New England Journal of Med. 1985-2003/Jun W5

(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

\*File 467: For information about updating status please see Help News467.

Set Items Description

--- -----

Cost is in DialUnits

?ds

Set	Items	Description
S1	13	E1-E6
S2	11	'GLU29'
S3	45	'GLU29'
S4	0	S3 AND CHOLERA?
S5	160	GLU (2N) 29
S6	8	S5 AND CHOLERA?

?e glu

Ref	Items	Index-term
E1	2	GLT5
E2	8	GLT50
E3	84106	*GLU
E4	175	GLU //RNA, TRANSFER,
E5	6	GLU ALA
E6	1	GLU ALLELE
E7	1	GLU A1
E8	1	GLU COSE
E9	1	GLU DECARBOXYLASE EC 4.1.1.15
E10	1	GLU EXCITATORY TRANSMISSION
E11	1	GLU GLUCOAMYLASE
E12	2	GLU GLUCOSE

Enter P or PAGE for more

?e glu2

Ref	Items	Index-term
E1	52	GLU199
E2	9	GLU199GLN
E3	250	*GLU2
E4	3	GLU2ASP
E5	1	GLU2GENE
E6	5	GLU2GLU3
E7	1	GLU2H
E8	1	GLU2H4
E9	1	GLU2LYS
E10	1	GLU2LYS2
E11	1	GLU2L4
E12	3	GLU2O

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	1	GLU2O8
E14	1	GLU2O9
E15	2	GLU2SUP
E16	151	GLU2O
E17	5	GLU2OALA
E18	4	GLU2OALA20PHE
E19	1	GLU20FWDARWLYS
E20	7	GLU200
E21	12	GLU200LYS
E22	38	GLU201
E23	5	GLU201GLN
E24	3	GLU2015

Enter P or PAGE for more

?p

Ref	Items	Index-term
E25	55	GLU202
E26	1	GLU202-GLN
E27	1	GLU202CNTDOTZINCCNTDOH2O
E28	8	GLU203
E29	1	GLU203GLY
E30	95	GLU204
E31	3	GLU204C
E32	8	GLU204GLN
E33	21	GLU205
E34	36	GLU206
E35	1	GLU206LYS
E36	4	GLU2069

Enter P or PAGE for more

?p

Ref	Items	Index-term
E37	34	GLU207
E38	5	GLU207LYS
E39	31	GLU208
E40	25	GLU209
E41	2	GLU2096
E42	218	GLU21
E43	4	GLU21ARG
E44	6	GLU21GLN
E45	28	GLU210
E46	5	GLU210STOP
E47	19	GLU211
E48	1	GLU2116

Enter P or PAGE for more

?p

Ref	Items	Index-term
E49	42	GLU212
E50	1	GLU212ALA

?p

Ref	Items	Index-term
E1	1	GLU212ALA
E2	1	GLU212ASP
E3	1	GLU212GLN
E4	4	GLU212LYS
E5	7	GLU213
E6	21	GLU214
E7	14	GLU215
E8	2	GLU215A
E9	3	GLU215ASP
E10	48	GLU216
E11	1	GLU216CNTDOTARG129
E12	1	GLU216FWDARWASP

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	7	GLU216STOP
E14	40	GLU217
E15	1	GLU217ALA
E16	11	GLU218
E17	7	GLU2181
E18	1	GLU2181-VAL2243
E19	2	GLU2189
E20	37	GLU219
E21	1	GLU219ALA
E22	6	GLU219ASP

E23 3 GLU219LYS  
E24 131 GLU22

Enter P or PAGE for more

?p

Ref	Items	Index-term
E25	1	GLU22ASP
E26	1	GLU22FWDARWGLN
E27	1	GLU22GLN
E28	1	GLU22LY
E29	12	GLU22LYS
E30	27	GLU220
E31	8	GLU221
E32	5	GLU221B
E33	37	GLU222
E34	3	GLU222GLN
E35	3	GLU222H
E36	12	GLU223

Enter P or PAGE for more

?p

Ref	Items	Index-term
E37	28	GLU224
E38	1	GLU224ASP
E39	5	GLU224GLY
E40	31	GLU225
E41	18	GLU226
E42	9	GLU227
E43	3	GLU228
E44	9	GLU229
E45	5	GLU229ALA
E46	4	GLU229LYS
E47	64	GLU23
E48	1	GLU23GAG

Enter P or PAGE for more

?p

Ref	Items	Index-term
E49	5	GLU23ILE
E50	15	GLU23LYS

?p

Ref	Items	Index-term
E1	15	GLU23LYS
E2	55	GLU230
E3	35	GLU231
E4	32	GLU232
E5	3	GLU2327
E6	60	GLU233
E7	1	GLU233-TO-LYS MISSENSE MUTATION
E8	5	GLU233GLN
E9	1	GLU233LYS
E10	1	GLU2331
E11	1	GLU2338
E12	19	GLU234

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	6	GLU2347
E14	47	GLU235
E15	1	GLU235DEL
E16	1	GLU235FWDARW0
E17	3	GLU235LYS
E18	6	GLU236

E19	36	GLU237
E20	1	GLU237FWDARWGLY
E21	28	GLU237GLY
E22	1	GLU237GLY VARIANT
E23	40	GLU238
E24	3	GLU238GLN

Enter P or PAGE for more

?p

Ref	Items	Index-term
E25	20	GLU239
E26	45	GLU24
E27	2	GLU24LYS16ALA60
E28	36	GLU240
E29	15	GLU240CYS
E30	6	GLU240GLN
E31	22	GLU240LYS
E32	27	GLU241
E33	6	GLU241GLN
E34	29	GLU242
E35	1	GLU242FWDARWGLN
E36	2	GLU242LYS

Enter P or PAGE for more

?p

Ref	Items	Index-term
E37	6	GLU242STOP
E38	22	GLU243
E39	1	GLU243FWDARWGLY
E40	3	GLU243GLY
E41	23	GLU244
E42	14	GLU244ASP
E43	1	GLU244FWDARWLYS
E44	1	GLU2447
E45	42	GLU245
E46	1	GLU245FWDARWLYS
E47	2	GLU245GLN
E48	3	GLU245LYS

Enter P or PAGE for more

?p

Ref	Items	Index-term
E49	3	GLU245VAL
E50	33	GLU246

?p

Ref	Items	Index-term
E1	33	GLU246
E2	19	GLU247
E3	5	GLU247GLY
E4	1	GLU248
E5	22	GLU249
E6	7	GLU249GLN
E7	1	GLU249LYS
E8	6	GLU249X
E9	59	GLU25
E10	4	GLU25ASP
E11	12	GLU25CYS
E12	14	GLU250

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	1	GLU250ALA
E14	7	GLU2503

E15	9	GLU251
E16	2	GLU251ALA
E17	2	GLU252
E18	16	GLU253
E19	17	GLU254
E20	5	GLU254ALA
E21	7	GLU254GLY
E22	61	GLU255
E23	1	GLU255FWDARW
E24	1	GLU255FWDARWGLN

Enter P or PAGE for more

?s e10

S7 4 'GLU25ASP'

?p

Ref	Items	Index-term
E25	9	GLU255LYS
E26	4	GLU255VAL
E27	55	GLU256
E28	10	GLU256LYS
E29	1	GLU256STOP
E30	56	GLU257
E31	1	GLU257FWDARWALA
E32	1	GLU257GIN
E33	10	GLU257GLN
E34	9	GLU258
E35	4	GLU258LYS
E36	19	GLU259

Enter P or PAGE for more

?p

Ref	Items	Index-term
E37	7	GLU259VAL
E38	45	GLU26
E39	13	GLU26ALA
E40	16	GLU260
E41	30	GLU261
E42	1	GLU261ALA
E43	29	GLU262
E44	2	GLU262ASP
E45	1	GLU262FWDARWASP
E46	1	GLU262FWDARWGLN
E47	7	GLU263
E48	28	GLU264

Enter P or PAGE for more

?p

Ref	Items	Index-term
E49	1	GLU264VAL
E50	26	GLU265

?p

Ref	Items	Index-term
E1	26	GLU265
E2	1	GLU265LYS
E3	29	GLU266
E4	12	GLU267
E5	5	GLU267LYS
E6	29	GLU268
E7	5	GLU268LYS
E8	1	GLU268STOP
E9	105	GLU269
E10	3	GLU269FWDARWASP
E11	2	GLU269FWDARWCYS
E12	1	GLU269FWDARWGLN

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	1	GLU269FWDARWHIS
E14	7	GLU269PRO
E15	326	GLU27
E16	7	GLU27CL
E17	25	GLU27GLN
E18	35	GLU27GLU
E19	7	GLU27L
E20	64	GLU270
E21	2	GLU270GIN
E22	5	GLU270GLN
E23	3	GLU270STOP
E24	7	GLU270VAL

Enter P or PAGE for more

?p

Ref	Items	Index-term
E25	5	GLU2703
E26	21	GLU271
E27	10	GLU271LYS
E28	8	GLU271STOP
E29	1	GLU271STOP NOVEL DE-NOVO SPONTANEOUS POINT MUT
E30	6	GLU271TRP
E31	1	GLU2717
E32	31	GLU272
E33	3	GLU272ARG
E34	24	GLU273
E35	7	GLU273ALA
E36	30	GLU274

Enter P or PAGE for more

?p

Ref	Items	Index-term
E37	9	GLU274LYS
E38	37	GLU275
E39	15	GLU276
E40	24	GLU277
E41	1	GLU277GLN
E42	6	GLU277GLY
E43	6	GLU277LYS
E44	1	GLU277VAL
E45	27	GLU278
E46	19	GLU279
E47	6	GLU279SER
E48	45	GLU28

Enter P or PAGE for more

?p

Ref	Items	Index-term
E49	7	GLU28GLN
E50	40	GLU280

?p

Ref	Items	Index-term
E1	40	GLU280
E2	7	GLU280ALA
E3	6	GLU280GLN
E4	2	GLU280GLY
E5	6	GLU280LYS
E6	6	GLU281
E7	42	GLU282
E8	6	GLU282ALA
E9	6	GLU282GLY

E10 7 GLU283  
E11 9 GLU284  
E12 3 GLU284GLN

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	3	GLU2843
E14	23	GLU285
E15	7	GLU285ALA
E16	2	GLU285GIN
E17	12	GLU285GLN
E18	2	GLU285LYS
E19	71	GLU286
E20	7	GLU286ASP
E21	7	GLU286CYS
E22	1	GLU286TYR288
E23	22	GLU287
E24	7	GLU287MET

Enter P or PAGE for more

?p

Ref	Items	Index-term
E25	19	GLU288
E26	1	GLU288ALA
E27	12	GLU289
E28	1	GLU289FWDARWLYS
E29	45	GLU29
E30	36	GLU290
E31	6	GLU2904GLY
E32	6	GLU291
E33	4	GLU291LYS
E34	25	GLU292
E35	7	GLU293
E36	2	GLU294

Enter P or PAGE for more

?ds

Set	Items	Description
S1	13	E1-E6
S2	11	'GLU29'
S3	45	'GLU29'
S4	0	S3 AND CHOLERA?
S5	160	GLU (2N) 29
S6	8	S5 AND CHOLERA?
S7	4	'GLU25ASP'

?t s7/free/all

>>>"FREE" is not a valid format name in file(s): 399

7/8/1 (Item 1 from file: 155)

DIALOG(R)File 155:(c) format only 2003 The Dialog Corp. All rts. reserv.

14465467 22477042 PMID: 12589569

**Engineering new metal specificity in EF-hand peptides.**

11 20 2002

7/8/2 (Item 1 from file: 34)

DIALOG(R)File 34:(c) 2003 Inst for Sci Info. All rts. reserv.

11430924 Genuine Article#: 652DU Number of References: 31

**Title: Engineering new metal specificity in EF-hand peptides** (ABSTRACT AVAILABLE)

Publication date: 20030200

Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, INORGANIC & NUCLEAR



Descriptors--Author Keywords: calmodulin ; EF-hands ; metal chelation ;  
fluorescence ; biosensors  
Identifiers--Keyword Plus(R) : CALCIUM-BINDING MOTIF; CALMODULIN; PROTEIN;  
LUMINESCENCE; SELECTIVITY; CONSTANTS; TOXICITY; AFFINITY; NUMBER; CELLS

7/8/3 (Item 1 from file: 73)  
11974088 EMBASE No: 2003084806  
Engineering new metal specificity in EF-hand peptides  
2003

7/8/4 (Item 1 from file: 172)  
DIALOG(R)File 172:(c) 2003 Elsevier Science B.V. All rts. reserv.

02886768 EMBASE No: 2003084806  
Engineering new metal specificity in EF-hand peptides  
2003  
AUTHOR KEYWORDS: Calmodulin; EF-hands; Metal chelation; Fluorescence;  
Biosensors  
?logoff hold

26jun03 08:48:21 User228206 Session D2003.6  
\$0.51 0.158 DialUnits File155  
\$0.00 1 Type(s) in Format 8  
\$0.00 1 Types  
\$0.51 Estimated cost File155  
\$0.39 0.070 DialUnits File5  
\$0.39 Estimated cost File5  
\$1.95 0.106 DialUnits File34  
\$0.00 1 Type(s) in Format 8  
\$0.00 1 Types  
\$1.95 Estimated cost File34  
\$0.36 0.088 DialUnits File35  
\$0.36 Estimated cost File35  
\$0.38 0.070 DialUnits File48  
\$0.38 Estimated cost File48  
\$0.33 0.088 DialUnits File65  
\$0.33 Estimated cost File65  
\$0.66 0.088 DialUnits File71  
\$0.66 Estimated cost File71  
\$1.46 0.158 DialUnits File73  
\$0.00 1 Type(s) in Format 6  
\$0.00 1 Types  
\$1.46 Estimated cost File73  
\$0.30 0.070 DialUnits File91  
\$0.30 Estimated cost File91  
\$0.31 0.088 DialUnits File94  
\$0.31 Estimated cost File94  
\$0.21 0.088 DialUnits File98  
\$0.21 Estimated cost File98  
\$0.48 0.088 DialUnits File135  
\$0.48 Estimated cost File135  
\$0.31 0.088 DialUnits File144  
\$0.31 Estimated cost File144  
\$0.23 0.053 DialUnits File149  
\$0.23 Estimated cost File149  
\$0.66 0.123 DialUnits File156  
\$0.66 Estimated cost File156  
\$0.26 0.088 DialUnits File159  
\$0.26 Estimated cost File159  
\$0.40 0.088 DialUnits File162  
\$0.40 Estimated cost File162  
\$0.31 0.088 DialUnits File164  
\$0.31 Estimated cost File164  
\$0.81 0.088 DialUnits File172  
\$0.00 1 Type(s) in Format 8  
\$0.00 1 Types  
\$0.81 Estimated cost File172  
\$0.43 0.123 DialUnits File266

\$0.43 Estimated cost File266  
\$0.18 0.053 DialUnits File369  
\$0.18 Estimated cost File369  
\$0.25 0.070 DialUnits File370  
\$0.25 Estimated cost File370  
\$1.55 0.123 DialUnits File399  
\$1.55 Estimated cost File399  
\$1.95 0.106 DialUnits File434  
\$1.95 Estimated cost File434  
\$0.34 0.070 DialUnits File442  
\$0.34 Estimated cost File442  
\$0.42 0.088 DialUnits File444  
\$0.42 Estimated cost File444  
\$0.45 0.070 DialUnits File467  
\$0.45 Estimated cost File467  
OneSearch, 27 files, 2.481 DialUnits FileOS  
\$0.70 TELNET  
\$16.59 Estimated cost this search  
\$16.59 Estimated total session cost 2.481 DialUnits

### Status: Signed Off. (3 minutes)

08248393 94314415 PMID: 8039872

**Construction and characterization of recombinant *Vibrio cholerae* strains producing inactive cholera toxin analogs.**

Hase C C; Thai L S; Boesman-Finkelstein M; Mar V L; Burnette W N; Kaslow H R; Stevens L A; Moss J; Finkelstein R A

Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia 65212.

Infection and immunity (UNITED STATES) Aug 1994, 62 (8) p3051-7,  
ISSN 0019-9567 Journal Code: 0246127

Contract/Grant No.: AI17312; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The catalytic A subunit of cholera toxin (CT-A) is capable of ADP-ribosylating the guanine nucleotide-binding protein, which regulates cell adenyl cyclase, leading to the life-threatening diarrhea of cholera. Amino acids involved in the enzymatic activity of CT-A have previously been identified. By means of site-directed mutagenesis, an analog of the CT-A subunit gene was created with codon **substitutions** for both Arg-7 and Glu-112, each of which has been shown to produce **subunits** lacking ADP-ribosyltransferase activity. The mutated gene fragment was exchanged for the wild-type copy in the previously cloned ctxAB operon from El Tor biotype, Ogawa serotype *Vibrio cholerae* strain 3083, which produces CT-2. Further, the zonula occludens toxin gene, zot, was inactivated by an insertional **mutation** to create the new plasmid construct pCT-2\*. Additionally, a DNA fragment encoding the B **subunit** of CT-1 (CT produced by classical biotype, Inaba serotype V. cholerae strain 569B) was exchanged for the homologous part in pCT-2\*, resulting in the creation of pCT-1\*. These plasmid constructs were introduced into the CT-negative V. cholerae **mutant** strain JBK70 (El Tor biotype, Inaba serotype); CT-A-B+ derivatives CVD101 and CVD103 of classical biotype Ogawa and Inaba serotype strains 395 and 569B, respectively; El Tor biotype Inaba and Ogawa serotype strains C6706 and C7258, respectively, recently isolated in Peru; and O139 (synonym Bengal) strain SG25-1 from the current epidemic in India. Recombinant toxins (CT-1\* and CT-2\*), partially purified from culture supernatants of transformed JBK70, were shown to be inactive on mouse Y1 adrenal tumor cells and in an in vitro ADP-ribosyltransferase assay. CT-1\* and CT-2\* reacted with polyclonal and monoclonal antibodies against both A and B **subunits** of CT. The toxin analogs reacted with antibodies against CT-A and CT-B on cellulose acetate strips and in a GM1 enzyme-linked immunosorbent assay; they reacted appropriately with B- **subunit** epitope-specific monoclonal antibodies in checkerboard immunoblots, and they formed precipitin bands with GM1-ganglioside in Ouchterlony tests. However, the reactions of the **modified** proteins with anti-A- **subunit** monoclonal antibodies were weaker than the reactions with wild-type holotoxins. V. cholerae strains carrying ctxA\*, with either ctxB-1 or ctxB-2, and inactivated zot genes were created by homologous recombination. The recombinant strains and the purified toxin analogs were inactive in the infant rabbit animal model. (ABSTRACT TRUNCATED AT 400 WORDS)

Tags: Animal; Support, U.S. Gov't, P.H.S.

Descriptors: \*Cholera Toxin--biosynthesis--BI; \*Cholera Vaccines--biosynthesis--BI; \*Vaccines, Synthetic--biosynthesis--BI; \*Vibrio cholerae--genetics--GE; Base Sequence; Cholera Toxin--genetics--GE; Cholera Toxin--toxicity--TO; Genes, Bacterial; Molecular Sequence Data; Plasmids; Rabbits

CAS Registry No.: 0 (Cholera Vaccines); 0 (Plasmids); 0 (Vaccines, Synthetic); 9012-63-9 (Cholera Toxin)

Record Date Created: 19940824

Record Date Completed: 19940824

08597972 95286289 PMID: 7768621

**Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.**

Fontana M R; Manetti R; Giannelli V; Magagnoli C; Marchini A; Olivieri R; Domenighini M; Rappuoli R; Pizza M

IRIS, Biocine Immunobiological Research Institute Siena, Italy.

Infection and immunity (UNITED STATES) Jun 1995, 63 (6) p2356-60,  
ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Using computer modelling, we have identified some of the residues of the A subunit of cholera toxin (CT) and heat-labile toxin that are involved in NAD binding, catalysis, and toxicity. Here we describe the site-directed mutagenesis of the CT gene and the construction of CT mutants. Nine **mutations** of the A **subunit** gene were generated. Six of them encoded proteins that were fully assembled in the AB5 structure and were nontoxic; these proteins were CT-D53 (Val-53-->Asp), CT-K63 (Ser-63-->Lys), CT-K97 (Val-97-->Lys), CT-K104 (Tyr-104-->Lys), CT-S106 (Pro-106-->Ser), and the double **mutant** CT-D53/K63 (Val-53-->Asp, Ser-63-->Lys). Two of the **mutations** encoded proteins that were assembled into the AB5 structure but were still toxic; these proteins were CT-H54 (Arg-54-->His) and CT-N107 (His-107-->Asn). Finally, one of the **mutant** proteins, CT-E114 (Ser-114-->Glu), was unable to assemble the A and the B **subunits** and produced only the B oligomer. The six nontoxic **mutants** were purified from the culture supernatants of recombinant **Vibrio cholerae** strains and further characterized. The CT-K63 **mutant**, which was the most efficient in assembly of the AB5 structure, was used to immunize rabbits and was shown to be able to induce neutralizing antibodies against both the A and B **subunits**. This molecule may be useful for the construction of improved vaccines against cholera.

Tags: Animal; Support, Non-U.S. Gov't

Descriptors: \*Cholera Toxin--immunology--IM; Base Sequence; Cholera Vaccines--immunology--IM; Immunization; Molecular Sequence Data; Mutation; Rabbits; Structure-Activity Relationship

CAS Registry No.: 0 (Cholera Vaccines); 9012-63-9 (Cholera Toxin)

Record Date Created: 19950705

Record Date Completed: 19950705